Except for EGFR mutations accounted for acquired resistance to EGFR-TKIs in NSCLC, aberrantly activated alternative pathways, such as MET amplification and STAT3 hyperactivation, may also contribute to the EGFR-TKIs acquired resistance 13-15. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.